Clinical trial
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
NCT00337662 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00337662 |
|---|---|
| Title | Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia |
| Official title | Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder |
| Intervention type | Drug |
| Interventions | olanzapine, risperidone |
| Enrollment | 628 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jun 16, 2006 |
| Last update posted | Feb 17, 2010 |
| Countries | Argentina, Russia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: